Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iCAD and Fuji partner

This article was originally published in The Gray Sheet

Executive Summary

Fujifilm Medical Systems will offer iCAD's SecondLook Digital and TotalLook computer-aided detection products on its digital mammography systems, including the recently approved FCRm computed radiography system, the firms announce Sept. 8. The agreement is a strategic step for iCAD, whose competitor R2 Technology (ImageChecker) was acquired by imaging firm Hologic in April (1"The Gray Sheet" May 8, 2006, p. 13)...

You may also be interested in...



iCAD Sees Future In CR, Analog Systems After Hologic Buys Competitor R2

With its former chief competitor reportedly turning to digital technologies, iCAD says it will seize on computed radiography and film-based customers

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel